📆 Tomorrow is the FINAL and most exciting day of the 42nd Annual CFS! Listen in as Yan Leyfman, MD, of MedNews Week, shares what he is most excited for ahead of tomorrow! #CFS24 👨⚕️ Learn more about the event at https://lnkd.in/e9648sEf
About us
OncLive is the official website for the Intellisphere, LLC Oncology Specialty Group, which publishes OncologyLive, Urologists in Cancer Care, Oncology Nursing News, and Oncology Fellows. The mission of OncLive is to arm oncology professionals with the resources and information they need to provide the best patient care. We cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. OncLive allows the Oncology Specialty Group to add features and tools not possible with print, such as social media feeds, breaking news, and live coverage from major oncology meetings.
- Website
-
http://onclive.com
External link for OncLive
- Industry
- Book and Periodical Publishing
- Company size
- 51-200 employees
- Headquarters
- Cranbury, NJ
- Type
- Privately Held
Locations
-
Primary
Get directions
2 Clarke Dr
Cranbury, NJ 08512, US
Employees at OncLive
-
Chandler Park, M.D., F.A.C.P.
Award Winning Oncologist| 3x NEJM Published Author| ASCO Faculty|Advisory Dean/Clinical Professor UofL Medical School|Kentucky Leader ASCO ASH NCCN…
-
Julie Ruff, RDN
National Account Manager | OncLive Medical®| Medical Affairs | Sales
-
Morgan Burum
Director of Sales
-
Gabrielle Gelchion
National Account Manager, Onclive Events™
Updates
-
Investigators hope to add a treatment option that has the potential to produce superior efficacy vs present ROS1 inhibitors for patients with ROS1+ NSCLC. Mass General Hospital Lyudmila Bazhenova, MD UC San Diego Health ROBERT H. LURIE COMPREHENSIVE CANCER CENTER OF NORTHWESTERN UNIVERSITY Stephen Liu Lombardi Comprehensive Cancer Center Alexander Drilon Memorial Sloan Kettering Cancer Center The Chinese University of Hong Kong #oncology #NSCLC https://lnkd.in/eGx4v7_a
-
Learn how NewYork-Prebyterian and Weill Cornell Medicine oncologists, Dr. Tessa Gigler and Dr. John Ng, devised a unique patient-centered approach to a complex cancer to achieve a successful outcome. Watch now: https://bit.ly/4gY7VsG #Sponsored
-
-
Hear Maurice Pérol, MD, present a pooled analysis of two pivotal Phase 2 trials assessing the efficacy and safety of taletrectinib in patients with advanced ROS1+ #NSCLC. Watch the full video here: https://lnkd.in/g2nQ79wz
-
The FDA has granted priority review to the NDA for avutometinib plus defactinib in KRAS-mutant recurrent low-grade serous ovarian cancer. #oncology #ovariancancer https://lnkd.in/e3ks5qgz
FDA Grants Priority Review to Avutometinib Plus Defactinib for KRAS+ Recurrent Low-Grade Serous Ovarian Cancer
onclive.com
-
With #FDAReport: The Regulatory Rundown ✅ 🔍 , we provide you with a monthly snapshot of all therapeutic options approved by the FDA spanning tumor types. The December edition is now LIVE! ✨
OncLive’s December Roundup of Key FDA Approvals in Oncology
OncLive on LinkedIn
-
In this latest episode of #OncLiveOnAir 🎙️, Stacey A. Cohen, MD, of Fred Hutch, discusses 🗣️ the evolving role of circulating tumor DNA in clinical decision-making for patients with colorectal cancer, particularly through findings from the CIRCULATE-Japan GALAXY trial. Tune in now 🎧 👉 : https://lnkd.in/eGcjWJ7d
-
-
#GiantsofCancerCare 🗣️: A humble mindset of the contributions he has made to genitourinary cancer care, Christopher J. Logothetis, MD, of MD Anderson Cancer Center, is also working to shape the next generation’s minds 🧠 of medicine to improve outcomes further. https://lnkd.in/eh7Y5TB4
A Sense of Culture and Community Sparked a Passion in Genitourinary Oncology
onclive.com
-
🚨 NEW EPISODE ALERT 🚨: In the latest installment of #OncLiveOnAir 🎙️, Jorge Eduardo Cortes, MD, of Georgia Cancer Center, discusses how the FDA approval of #luspatercept-aamt (#Reblozyl) has influenced first-line #MDS management, particularly for patients with #anemia. He also sheds light on: ⭐ How luspatercept compares with existing options like ESAs ⭐ The QOL benefits associated with luspatercept in symptomatic patients ⭐ The importance of risk stratification in lower-risk MDS ⭐ Ultimate goals of therapy in this population ⭐ Challenges that remain in lower-risk MDS management Listen now 🎧: https://lnkd.in/eGr4YUPy
-